NEW
YORK, July 14, 2023 /PRNewswire/ -- Jakubowitz
Law announces that an investigation into potential securities
fraud allegations has commenced on behalf of
shareholders of Bausch Health Companies Inc. (NYSE: BHC)
To be contacted by a member of our team, fill out the
form:
https://claimyourloss.com/securities/bausch-health-class-action-loss-submission-form/?id=42097&from=4
Further details on the investigation: The investigation
focuses on whether Bausch Health issued false and/or misleading
statements and/or failed to disclose information pertinent to
investors concerning its 2022 earnings and guidance and its patent
dispute over Xifaxan. On May 10,
2022, Bausch Health announced its first-quarter 2022
results, prompting the stock price to fall $3.50 per share. Analysts attributed the decline
to concerns around the Company's spin-off of Bausch + Lomb
Corporation, high debt levels, and anticipation over the Xifaxan
patent decision. On July 28, 2022,
the Company issued an update on the Xifaxan patent dispute case
between Bausch Health and Norwich.
In response to this news, market analysts downgraded Bausch Health
and its stock price fell an additional $3.58 per share, representing a decline of more
than 50% from its trading price just two months earlier.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities
fraud. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/bhc-fraud-alert-jakubowitz-law-is-investigating-bausch-health-companies-inc-in-connection-with-potential-violations-of-federal-securities-laws-301877143.html
SOURCE Jakubowitz Law